Market Size of Incretin-based Drugs Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Incretin Based Drugs Market Analysis
The incretin-based drugs market is expected to register a CAGR of 5.2% during the forecast period.
Initially, COVID-19 impacted the incretin-based drugs market in its initial phase due to the cancellation of elective procedures for chronic diseases, including diabetes. However, the virtual consultations for diabetes and rising awareness about the management of diabetes allowed patients to continue their incretin-based drug medication. COVID-19 also had an adverse impact on people with diabetes. For instance, according to an article published in the Journal of Pharmacy Practice in May 2022, COVID-19 was associated with a high mortality risk among diabetes mellitus (DM) patients. The studied market is expected to remain unaffected by the emergence of new variants of COVID-19 and is further expected to show a significant growth rate during the forecast period.
The incretin-based drugs market is expected to grow during the forecast period owing to the high burden of Type- 2 diabetes globally. For instance, as per the International Diabetes Federation (IDF) 2021 report, the number of adults (20-79 years) with diabetes was 536.6 million in 2021 and is predicted to reach 783.2 million by 2045. The prevalence of diabetes worldwide was 10.5% in 2021 and is projected to be 12.2% in 2045. The high burden of diabetes requires an incretin-based drug for normalizing blood glucose levels, thereby propelling market growth.
Furthermore, according to the Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, data published in May 2022, the obesity prevalence was 39.8% among adults aged 20 to 39 years, 44.3% among adults aged 40 to 59 years, and 41.5% among adults aged 60 and older. Obesity is one of the most important factors which are expected to drive the incidence of diabetes. Therefore, the high burden of obesity worldwide is also expected to drive market growth during the forecast period.
Additionally, as per a Statpearls article updated in August 2022, DPP-4 inhibitors are also called gliptins, a class of oral diabetic medications approved by the Food and Drug Administration (FDA) to treat type 2 diabetes mellitus in adults. The FDA-approved DPP-4 includes sitagliptin, saxagliptin, linagliptin, and alogliptin. Vildagliptin has approval from the European Medicines Agency (EMA) but not from the FDA. Therefore, the large number of available approved DPP-4 creates an opportunity for market players to manufacture and market incretin-based drugs during the forecast period.
Therefore, owing to the factors such as the high burden of diabetes and rising approvals of DPP-4, and advantages offered by the drugs in the management of diabetes, the studied market is anticipated to witness growth over the analysis period. However, lack of reimbursement and poor accessibility to drugs, especially in developing countries, are the factors expected to restrain the market growth during the forecast period.
